Statins, Mortality, and Major Adverse Cardiovascular Events Among US Veterans With Chronic Kidney Disease
Odeya Barayev, Chelsea E. Hawley, Helen Wellman, Hanna Gerlovin, Whitney Hsu, Julie M. Paik, Ernest I. Mandel, Christine K. Liu, Luc Djoussé, J. Michael Gaziano, David R. Gagnon, Ariela R. Orkaby · 2023
Read Statins, Mortality, and Major Adverse Cardiovascular Events Among US Veterans With Chronic Kidney Disease by Odeya Barayev, Chelsea E. Hawley, Helen Wellman, Hanna Gerlovin, Whitney Hsu, Julie M. Paik, Ernest I. Mandel, Christine K. Liu, Luc Djoussé, J. Michael Gaziano, David R. Gagnon, Ariela R. Orkaby (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10701610.txt.
Description
Odeya Barayev and co-authors ask whether statins help older veterans with kidney disease in a 2023 cohort study. Proof for statins to prevent heart disease and death in people with kidney disease has been thin.
The study used a trial-like design on health system and Medicare data for veterans over sixty-five with moderate kidney disease. All were within five years of diagnosis, with no past heart disease or statin use. Close to fifteen thousand veterans were tracked for death and major heart events. The design weighs statin starters against non-starters with care for bias. Readers get a large, real-world test of a common drug choice in kidney care.
Catalog record
| CREATOR | Odeya Barayev, Chelsea E. Hawley, Helen Wellman, Hanna Gerlovin, Whitney Hsu, Julie M. Paik, Ernest I. Mandel, Christine K. Liu, Luc Djoussé, J. Michael Gaziano, David R. Gagnon, Ariela R. Orkaby |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |